Endovascular treatment of infectious intracranial aneurysms: A single-center experience
Center (category theory)
Single Center
DOI:
10.4103/bc.bc_77_24
Publication Date:
2025-03-23T00:33:11Z
AUTHORS (12)
ABSTRACT
Infectious intracranial aneurysms (IIAs), a notable complication of infective endocarditis (IE), pose significant clinical challenges. This study delineates the outcomes, management strategies, and manifestations IIAs, drawing from single-center's experience. We conducted retrospective observational analysis at our institution, focusing on patients diagnosed with IE between 2016 2022 who were also found to have IIAs. Data was performed utilizing SAS statistical software alongside Microsoft Excel execute descriptive operations. Among 862 patients, 25 (2.9%) totaling 41 mycotic aneurysms. Of these, 18 had single aneurysm, while 7 multiple. The cohort's median age 45 years, an interquartile range 27-65 predominance male (68.3%). Ischemic hemorrhagic strokes observed in 58.6% 87.8% cases, respectively. Ruptured IIAs noted 58.5% instances, remainder unruptured. average diameter ruptured 3.3 mm, compared 2.1 mm for unruptured aneurysms, although this difference not statistically (P = 0.324). most frequent IIA locations distal segments posterior middle cerebral arteries. Patients experienced higher in-hospital mortality rates (29.1%) relative those (11.7%). Treatment administered 58.3% no interventions 0.001). modalities included surgical resection, n-butyl cyanoacrylate, coils, Onyx embolization. treated size 4.4 versus 2.0 untreated treated, majority either discharged home (21.4%) or other facilities (78.6%), mortalities reported group. findings suggest that endovascular treatment is viable effective option managing decisions tailored individual patient comorbidities. Further multicenter studies are recommended corroborate these refine strategies associated endocarditis.
SUPPLEMENTAL MATERIAL
Coming soon ....
REFERENCES (12)
CITATIONS (0)
EXTERNAL LINKS
PlumX Metrics
RECOMMENDATIONS
FAIR ASSESSMENT
Coming soon ....
JUPYTER LAB
Coming soon ....